ASX Share rice
Thu 13 May 2021 - 12:11:pm (Sydney)

CP1 Share Price

CANNPAL ANIMAL THERAPEUTICS LIMITEDCP1Pharmaceuticals, Biotechnology & Life Sciences

CP1 Company Information

Name:

CannPal Animal Therapeutics Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-Specialty & Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

45a Bay Street Double Bay NSW Australia 2028

Phone:

61 2 6108 3622

Founder, MD & Director:

Mr. Layton Patrick Mills

Head of Clinical Devel. and R&D:

Dr. Margaret Curtis

CFO & Company Sec.:

Mr. Baden Maxwell Bowen

Chief Scientific Officer & Member of Advisory Board:

Dr. Rayson Tan

Company Overview:

CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia. As of March 11, 2021, CannPal Animal Therapeutics Limited operates as a subsidiary of AusCann Group Holdings Ltd.

CP1 Share Price Information

Shares Issued:

93.13M

Dividend Yield:

%

Revenue (TTM):

$802.62K

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.022

Profit Margin:

-1.8239

Operating Margin (TTM):

$-1.85

Return On Assets (TTM):

$-0.41

Return On Equity (TTM):

$-0.71

Quarterly Revenue Growth (YOY):

0.15

Gross Profit(TTM):

$-1,070,575

Diluted Earnings Per Share (TTM):

$-0.016

CP1 CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$212.08K

Net Income:

$-1,703,571

Total Cash From Operating Activities:

$-1,389,216

Capital Expenditures:

$0

CP1 Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-1,703,570

Net Income:

$-1,703,570

Operating Income:

$-1,703,570

Total Revenue:

$765.26K

CP1 Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$334.22K

Total Stockholder Equity:

$1.61M

Total Assets:

$1.95M

Common Stock:

$6.98M

Retained Earnings:

$-7,093,425

Cash:

$1.92M

Total Current Liabilities:

$334.22K

Net Tangible Assets:

$1.61M

Total Current Assets:

$1.95M

Net Receivables:

$30.47K

Short-Term Investments:

$0

Accounts Payable:

$248.80K

Short-Term Investments:

$0

Non Current Liabilities Total:

$0

CP1 Share Price History

CP1 News

08 Nov, 2020
The CEO of CannPal Animal Therapeutics Limited (ASX:CP1) is Layton Mills, and this article examines the executive's...
21 Jul, 2020
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) ("CannPal" or "the Company") has released results from its safety and efficacy study for DermaCannĀ®, an oral nutraceutical developed for healthy skin and immune function for dogs.